NO990097L - Ny behandling av leptin-resistens - Google Patents

Ny behandling av leptin-resistens

Info

Publication number
NO990097L
NO990097L NO990097A NO990097A NO990097L NO 990097 L NO990097 L NO 990097L NO 990097 A NO990097 A NO 990097A NO 990097 A NO990097 A NO 990097A NO 990097 L NO990097 L NO 990097L
Authority
NO
Norway
Prior art keywords
leptin resistance
new treatment
leptin
pharmaceutically acceptable
resistance
Prior art date
Application number
NO990097A
Other languages
English (en)
Other versions
NO990097D0 (no
Inventor
George Henry Poste
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614740.0A external-priority patent/GB9614740D0/en
Priority claimed from GBGB9614751.7A external-priority patent/GB9614751D0/en
Priority claimed from GBGB9616407.4A external-priority patent/GB9616407D0/en
Priority claimed from GBGB9616412.4A external-priority patent/GB9616412D0/en
Priority claimed from GBGB9616409.0A external-priority patent/GB9616409D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO990097L publication Critical patent/NO990097L/no
Publication of NO990097D0 publication Critical patent/NO990097D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Metode for behandling og/eller profylakse av leptin-resistens og/eller tilstander forbundet med leptin-resistens og/eller komplikasjoner derav, hos mennesker eller andre pattedyr, hvilken metode omfatter innvendig administrering av en effektiv, ikke-toksisk og farmasøytisk akseptabel mengde av en leptin-sensibilisator eller et farmasøytisk akseptabelt derivat derav.
NO990097A 1996-07-12 1999-01-11 Ny behandling av leptin-resistens NO990097D0 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9614740.0A GB9614740D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9614751.7A GB9614751D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9616407.4A GB9616407D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616412.4A GB9616412D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616409.0A GB9616409D0 (en) 1996-08-05 1996-08-05 Novel treatment
PCT/GB1997/001928 WO1998002159A1 (en) 1996-07-12 1997-07-14 Novel treatment of leptine resistance

Publications (2)

Publication Number Publication Date
NO990097L true NO990097L (no) 1999-01-11
NO990097D0 NO990097D0 (no) 1999-01-11

Family

ID=27517363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990097A NO990097D0 (no) 1996-07-12 1999-01-11 Ny behandling av leptin-resistens

Country Status (12)

Country Link
EP (1) EP0921798A1 (no)
JP (1) JP2000514807A (no)
KR (1) KR20000023719A (no)
CN (1) CN1230114A (no)
AU (1) AU3552697A (no)
BR (1) BR9710272A (no)
CA (1) CA2260044A1 (no)
NO (1) NO990097D0 (no)
PL (1) PL331148A1 (no)
TR (1) TR199900056T2 (no)
TW (1) TW442288B (no)
WO (1) WO1998002159A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP2002543194A (ja) 1999-04-28 2002-12-17 ドクター・レディーズ・ラボラトリーズ・リミテッド 置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
WO1998002159A1 (en) 1998-01-22
KR20000023719A (ko) 2000-04-25
CN1230114A (zh) 1999-09-29
EP0921798A1 (en) 1999-06-16
AU3552697A (en) 1998-02-09
TR199900056T2 (xx) 1999-04-21
CA2260044A1 (en) 1998-01-22
JP2000514807A (ja) 2000-11-07
BR9710272A (pt) 1999-08-10
TW442288B (en) 2001-06-23
PL331148A1 (en) 1999-06-21
NO990097D0 (no) 1999-01-11

Similar Documents

Publication Publication Date Title
NO990097L (no) Ny behandling av leptin-resistens
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
MX9704793A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina.
AP9801272A0 (en) Use of an antagonist of ppar-alpha and ppr-gamma for the treatment of syndrom X.
NO20012978L (no) Fremgangsmåte og preparater for behandling av alvorlig bronkitt med et aerosolisert antibiotikum
PL316007A1 (en) Vaccine based on urease and method of treating infections caused by heliobacter
TJ270B (en) 5,6-Dichlorobenzimidazole derivatives process for their preparation pharmaceutical composition and method of treatment or prophylaxis of virus infections
NO983641L (no) Fremgangsmåte til behandling og farmasöytisk preparat
EA199900206A1 (ru) Способ лечения обычной простуды или аллергического ринита
WO2002049626A3 (en) The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
SE9603725D0 (sv) New teatment
MY122838A (en) Treating allergic and inflammatory conditions
FI954245A7 (fi) Koostumuksia ja menetelmiä immunovälitteisten tulehduksellisten häiriö iden hoitamiseksi
IL126539A (en) Pregnane derivatives with no alpha-17 substituent, their medicinal use and manufacturing method
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
EP0456842A4 (en) Medicinal application of m-csf
PT1156795E (pt) Utilizacao de acido succinico ou de seus sais e metodo de tratamento da resistencia a insulina
WO1993024117A3 (en) Medicaments for the treatment of anxiety
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
PT1140080E (pt) Utilizacao de riluzole no tratamento de traumatismos acusticos
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
ES2100941T3 (es) Uso de cromakalim/brl 38227 para el tratamiento de la hiperreactividad de las vias respiratorias.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO982854L (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
BR0013655A (pt) Uso de uma proteìna histacalina, e, método de tratamento ou de prevenção de rinite alérgica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application